Novartis AG (NVS) Stake Lessened by Hartwell J M Limited Partnership
Hartwell J M Limited Partnership cut its stake in Novartis AG (NYSE:NVS) by 5.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,253 shares of the company’s stock after selling 500 shares during the period. Hartwell J M Limited Partnership’s holdings in Novartis were worth $708,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of NVS. Sonora Investment Management LLC lifted its stake in Novartis by 93.9% during the fourth quarter. Sonora Investment Management LLC now owns 479 shares of the company’s stock valued at $41,000 after purchasing an additional 232 shares during the last quarter. Cornerstone Advisors Inc. lifted its position in shares of Novartis by 89.4% in the 3rd quarter. Cornerstone Advisors Inc. now owns 502 shares of the company’s stock valued at $43,000 after acquiring an additional 237 shares in the last quarter. Lavaca Capital LLC purchased a new stake in shares of Novartis in the 4th quarter valued at approximately $48,000. Focused Wealth Management Inc lifted its position in shares of Novartis by 29.9% in the 4th quarter. Focused Wealth Management Inc now owns 868 shares of the company’s stock valued at $74,000 after acquiring an additional 200 shares in the last quarter. Finally, Stelac Advisory Services LLC purchased a new stake in shares of Novartis in the 3rd quarter valued at approximately $113,000. Institutional investors and hedge funds own 11.18% of the company’s stock.
NVS stock opened at $88.85 on Friday. Novartis AG has a 12-month low of $72.30 and a 12-month high of $92.39. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.20 and a quick ratio of 0.97. The company has a market capitalization of $204.02 billion, a price-to-earnings ratio of 17.46, a P/E/G ratio of 1.92 and a beta of 0.69.
The business also recently announced an annual dividend, which will be paid on Wednesday, March 13th. Shareholders of record on Tuesday, March 5th will be given a $2.8646 dividend. This is an increase from Novartis’s previous annual dividend of $2.33. The ex-dividend date of this dividend is Monday, March 4th. This represents a yield of 3.27%. Novartis’s dividend payout ratio is presently 37.52%.
NVS has been the subject of several research analyst reports. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis in a research report on Thursday, October 18th. Wolfe Research initiated coverage on shares of Novartis in a research report on Tuesday, October 23rd. They issued an “outperform” rating for the company. Goldman Sachs Group upgraded shares of Novartis from a “neutral” rating to a “conviction-buy” rating in a research report on Friday, November 16th. Cowen upgraded shares of Novartis from a “market perform” rating to an “outperform” rating and set a $100.00 price target for the company in a research report on Monday, November 26th. Finally, Barclays downgraded shares of Novartis from an “equal weight” rating to a “sell” rating in a research report on Friday, December 7th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $90.94.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Read More: Swap
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.